U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated ...

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Rapport Therapeutics, Inc. yesterday and set a price target of $34.00. Tsao covers the Healthcare sector, focusing on stocks such as ...

SAN FRANCISCO & AUSTIN, Texas & EDINBURGH, Scotland--(BUSINESS WIRE)--October 07, 2025-- Rapport, the industry leader in real-time facial and full-body animation AI-powered avatars and a division of ...

Acquisition raises the technical and creative bar for real-time AI avatars with facial and full-body animation combined with cinematic-quality camera movement, enabling more lifelike, immersive, and ...

Rapport, the industry leader in real-time facial and full-body animation AI-powered avatars and a division of Speech Graphics, today announced its acquisition of Aquifer Motion, the AI-powered ...

Earlier this week, Rapport Therapeutics announced positive Phase 2a trial results for RAP-219 in refractory focal epilepsy, demonstrating best-in-class efficacy and good tolerability. This milestone ...

A complete guide to football positions and player roles in offense, defense and special teams. Learn how each position shapes the game. American football is a sport that has been around since the late ...